Emprumapimod
Emprumapimod (PF-07265803) is a potent, orally active and selective inhibitor of p38α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC50=100 pM) . Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain[1][2].
Product Specifications
CAS Number
765914-60-1
Product Name Alternative
PF-07265803
UNSPSC
12352005
Target
P38 MAPK
Type
Reference compound
Related Pathways
MAPK/ERK Pathway
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/emprumapimod.html
Purity
99.12
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(C)CN1C2=CC(C(N[C@H](C(N)=O)CCN(C)C)=O)=C(OC3=C(C=C(C=C3)F)F)C=C2C=N1
Molecular Formula
C24H29F2N5O3
Molecular Weight
473.52
References & Citations
[1]Dale Wright, et al. ARRY-797, a Potent and Selective Inhibitor of p38 Map Kinase, Inhibits LPS-Induced IL-6 and In Vivo Growth of RPMI-8226 Human Multiple Myeloma Cells.|[2]Antoine Muchir, et al. Abnormal p38α mitogen-activated protein kinase signaling in dilated cardiomyopathy caused by lamin A/C gene mutation. Hum Mol Genet. 2012 Oct 1;21 (19) :4325-33.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
P38α
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
